Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 8.
doi: 10.1007/s00467-025-06838-7. Online ahead of print.

SGLT2 inhibitors for kidney protection in children: expanding horizons beyond endocrinology

Costanza Pucci  1   2 , Davide Silvio Marazza  3 , Evgenia Preka  4   5 , Antonio Mastrangelo  6 , Giovanni Montini  6   7 , Olivia Boyer  4   8
Affiliations
Review

SGLT2 inhibitors for kidney protection in children: expanding horizons beyond endocrinology

Costanza Pucci et al. Pediatr Nephrol. .

Abstract

For over two decades, kidney protection in children has relied on angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), which present significant limitations. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as antidiabetic agents, have demonstrated significant benefits in preserving kidney function in adults with chronic kidney disease (CKD), regardless of diabetes status. The pathophysiology of paediatric CKD differs from adult CKD, with congenital anomalies of the kidney and urinary tract (CAKUT) as the predominant cause. Extrapolating adult data to paediatric patients is challenging, though preliminary studies suggest SGLT2i may mitigate hyperfiltration-related damage, reduce proteinuria, and slow CKD progression, on top of RAS-blockers. Recent paediatric case series and small clinical trials have shown promising results, though larger controlled studies are needed to confirm efficacy and safety. The ongoing DOUBLE PRO-TECT Alport trial represents a significant step toward evaluating SGLT2i kidney protection in children. While current data suggest potential benefits, careful assessment of adverse effects such as euglycaemic ketoacidosis (EuDKA) and calcium phosphorus imbalances is crucial. This review aims to explore the mechanism of action, clinical evidence, and future perspectives of SGLT2i in paediatric CKD, highlighting their potential as a novel therapeutic strategy beyond diabetes management.

Keywords: Chronic kidney disease; Kidney protection; Paediatrics; Proteinuria; SGLT2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: All performed procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent: Not applicable. Competing interest: The authors declare that they have no competing interests.

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117–S314. https://doi.org/10.1016/j.kint.2023.10.018 - DOI
    1. Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133–141. https://doi.org/10.2215/cjn.04010609 - DOI - PubMed
    1. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720 - DOI - PubMed
    1. Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389 - DOI - PubMed
    1. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925 - DOI - PubMed

LinkOut - more resources